| Glial Cell Derived Neurotrophic Factor (GDNF) | |
|---|---|
| Gene | [GDNF](/genes/gdnf) |
| UniProt | P39905 |
| PDB | 1AGQ, 1QAU |
| Mol. Weight | 13.3 kDa (mature), 20-25 kDa (prepro-GDNF) |
| Localization | Secreted, Extracellular space |
| Family | GDNF family (TGF-β superfamily) |
| Diseases | [Parkinson's Disease](/diseases/parkinsons-disease), [Amyotrophic Lateral Sclerosis](/diseases/als) |
Glial Cell Derived Neurotrophic Factor (GDNF) is a potent neurotrophin encoded by the GDNF gene that promotes the survival and maintenance of various neuronal populations, particularly dopaminergic and motor neurons[1]. This secreted protein belongs to the GDNF family within the TGF-β superfamily and is initially synthesized as a preproprotein (20-25 kDa) that is proteolytically processed to a mature, active form of approximately 13.3 kDa[2]. GDNF is essential for the development and maintenance of the dopaminergic nigrostriatal system, making it a leading candidate for Parkinson's disease therapy[3].
Discovered in 1973, GDNF was the first member of a distinct family of neurotrophic factors that includes neurturin (NRTN), artemin (ARTN), persephin (PSPN), and the GDNF receptor components[4].
GDNF undergoes complex post-translational processing:
| Precursor Form | Size | Processing |
|---|---|---|
| Prepro-GDNF | 20-25 kDa | Signal peptide cleavage |
| Pro-GDNF | ~15 kDa | Dimerization |
| Mature GDNF | 13.3 kDa | Proteolytic cleavage |
The mature GDNF forms a homodimer and is secreted as an active form[2:1].
GDNF signals through a unique bipartite receptor system:
GFRα1 (GDNF Family Receptor Alpha 1)
Ret (Rearranged during transfection)
Alternative receptor combinations:
GDNF is essential for dopaminergic neuron survival:
GDNF supports spinal cord motor neurons:
GDNF supports additional neuron types:
GDNF is central to PD therapeutic strategies:
GDNF has been tested in PD clinical trials:
| Trial | Outcome |
|---|---|
| Phase I (1992) | Promising motor improvement |
| Phase II (1999) | Mixed results, controversy |
| Phase III (2003) | No significant benefit |
| Continued studies | AAV-GDNF approaches |
Controversy around delivery methods and trial design continues to drive research[9].
New strategies to overcome delivery challenges:
GDNF has potential therapeutic applications in ALS:
GDNF promotes recovery in spinal cord injury models:
Emerging evidence for psychiatric applications:
GDNF structure is well-characterized:
| Feature | Details |
|---|---|
| Structure | Homodimer |
| PDB entries | 1AGQ, 1QAU, 2RMF |
| Fold | TGF-β family (cysteine knot) |
| Dimerization | Required for activity |
The crystal structure reveals a cysteine knot motif characteristic of the TGF-β superfamily[2:2].
| Factor | Primary Receptor | Primary Target |
|---|---|---|
| GDNF | GFRα1/Ret | Dopaminergic, motor neurons |
| Neurturin | GFRα2/Ret | Motor neurons, autonomic |
| Artemin | GFRα3/Ret | Sensory, autonomic |
| Persephin | GFRα4/Ret | Motor neurons |
Sortwell CE, Gray BC. Understanding the role of GDNF in Parkinson's disease. Neuropharmacology. 2020. ↩︎ ↩︎ ↩︎
Airaksinen MS, Saarma M. The GDNF family: signaling, biological functions and therapeutic value. Nature Reviews Neuroscience. 2002. ↩︎ ↩︎ ↩︎ ↩︎
Kordower JH, Bjorklund A. Trophic factor gene therapy for Parkinson's disease. Movement Disorders. 2019. ↩︎ ↩︎ ↩︎
Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for dopaminergic and motor neurons. Science. 1993. ↩︎ ↩︎
Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini MP, Pollock RA, Hefti F, et al. Characterization of a multicomponent receptor for GDNF. Nature. 1996. ↩︎ ↩︎
Baloh RH, Enomoto H, Johnson EM Jr, Milbrandt J. [The GDNF family ligands and receptors](https://doi.org/10.1016/S0301-0082(00). Progress in Neurobiology. 2000. ↩︎
Gowing G, Svendsen CN. GDNF delivery for ALS. Experimental Neurology. 2020. ↩︎ ↩︎
Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, Simmons L, Moffet B, Vandlen RA, Koliatsos VE, et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science. 1994. ↩︎
Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Langston JW, Laws ER Jr, Lozano AM, Penn RD, Simpson RK Jr, Stacy M, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003. ↩︎
Bartus RT, Brown L, Wilson A, Kruegel B, Svidritskiy E, Dean RL, blanda J, Chu Y, Kordower JH. Proper statistical analysis of phase II clinical trial data leads to different conclusions about AAV-GDNF efficacy in Parkinson's disease. JAMA Neurology. 2021. ↩︎
Blesch A, Tuszynski MH. Spinal cord injury: recapitulating development to promote regeneration. Nature Reviews Neuroscience. 2017. ↩︎
Saarma M, Goldman D. GDNF in depression. Neuropharmacology. 2020. ↩︎
Ivanova L, Bakhshetyan K, Deng H, Warren B, Rodriguez B, Kordower JH. AAV vector-mediated gene delivery to CNS: applications in Parkinson's disease therapy. Neuromuscular Disorders. 2020. ↩︎
Kratochwil NA, Goyal R, Mehta A. Combination approaches with neurotrophic factors in CNS disorders. Drug Discovery Today. 2020. ↩︎
Moore MW, Klein RD, Fariñas I, Sauer H, Armanini M, Phillips H, Reichardt LF, Ryan AM, Carver-Moore K, Rosenthal A. Renal and neuronal abnormalities in mice lacking GDNF. Nature. 1996. ↩︎